-
1
-
-
0028034160
-
How the pharmaceutical industry brings an antibiotic drug to market in the United States
-
Billstein SA: How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob Agents Chemother 1994, 38:2679-2682.
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 2679-2682
-
-
Billstein, S.A.1
-
2
-
-
0030921538
-
Emergent antibiotic resistance: Health risks and economic impact
-
Cassell GH: Emergent antibiotic resistance: health risks and economic impact. FEMS Immunol Med Microbiol 1997, 18:271-274. This paper describes current problems of bacterial drug resistance and considers consequent socio-economic issues.
-
(1997)
FEMS Immunol Med Microbiol
, vol.18
, pp. 271-274
-
-
Cassell, G.H.1
-
3
-
-
0039229975
-
Evolution of antibiotic resistance
-
Baquero F, Blazquez J: Evolution of antibiotic resistance. Trends Ecol Evol 1997, 12:482-487. This paper summarises the principal mechanisms of resistance to antibacterial agents and describes the genetic basis of acquired drug resistance.
-
(1997)
Trends Ecol Evol
, vol.12
, pp. 482-487
-
-
Baquero, F.1
Blazquez, J.2
-
4
-
-
0031037207
-
The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics
-
Chopra I, Hodgson J, Metcalf B, Poste G: The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 1997, 41:497-503. This paper discusses various strategies for drug discovery and describes the molecular techniques that will permit the targeting of products associated with infection.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 497-503
-
-
Chopra, I.1
Hodgson, J.2
Metcalf, B.3
Poste, G.4
-
5
-
-
0030774640
-
New strategies for antibacterial drug design
-
Knowles DJC: New strategies for antibacterial drug design. Trends Microbiol 1997, 5:379-383. This paper provides a historical perspective on drug discovery strategies and also describes the new molecular techniques thai will permit the targeting of bacterial infection processes.
-
(1997)
Trends Microbiol
, vol.5
, pp. 379-383
-
-
Knowles, D.J.C.1
-
7
-
-
0029794181
-
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
-
Pan X-S, Ambler J, Mehtar S, Fisher ML: Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996, 40:2321-2326.
-
(1996)
Antimicrob Agents Chemother
, vol.40
, pp. 2321-2326
-
-
Pan, X.-S.1
Ambler, J.2
Mehtar, S.3
Fisher, M.L.4
-
8
-
-
0030757351
-
The chemistry and biological profile of trovafloxacin
-
Brighty KE, Gootz TD: The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997, 39(Suppl B):1-14. In addition to describing trovafloxacin, this paper provides a very useful summary of structure/function relationships for other new fluoroquinolones.
-
(1997)
J Antimicrob Chemother
, vol.39
, Issue.SUPPL. B
, pp. 1-14
-
-
Brighty, K.E.1
Gootz, T.D.2
-
9
-
-
0031306984
-
Grepafloxacin - Focus on respiratory infections
-
Geddes AM: Grepafloxacin - focus on respiratory infections. J Antimicrob Chemother 1997, 40(suppl A):1-4.
-
(1997)
J Antimicrob Chemother
, vol.40
, Issue.SUPPL. A
, pp. 1-4
-
-
Geddes, A.M.1
-
10
-
-
0030831857
-
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
-
Bauernfeind A: Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997, 40:639-651.
-
(1997)
J Antimicrob Chemother
, vol.40
, pp. 639-651
-
-
Bauernfeind, A.1
-
11
-
-
0347518714
-
In vitro and in vivo activities of new nitroimidazole derivatives against M. tuberculosis (MTB)
-
Washington DC: American Society for Microbiology
-
Cynamon M, Lang M, O'Reilly T, Chmielewski A, Klemens S: In vitro and in vivo activities of new nitroimidazole derivatives against M. tuberculosis (MTB). [Abstract F-30]. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sept 27-Oct 1; San Francisco. Washington DC: American Society for Microbiology; 1997:151.
-
(1997)
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sept 27-Oct 1; San Francisco
, pp. 151
-
-
Cynamon, M.1
Lang, M.2
O'Reilly, T.3
Chmielewski, A.4
Klemens, S.5
-
12
-
-
0031409343
-
Molecular action of anti-mycobacterial agents
-
Chopra I, Brennan P: Molecular action of anti-mycobacterial agents. Tubercle Lung Dis 1998, 78:89-98. This paper provides a summary of the mechanisms of action of established antimycobacterial drugs and describes new agents in development.
-
(1998)
Tubercle Lung Dis
, vol.78
, pp. 89-98
-
-
Chopra, I.1
Brennan, P.2
-
13
-
-
0031931286
-
Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages
-
Sato K, Akaki T, Tomioka H: Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. J Antimicrob Chemother 1998, 41:77-83.
-
(1998)
J Antimicrob Chemother
, vol.41
, pp. 77-83
-
-
Sato, K.1
Akaki, T.2
Tomioka, H.3
-
15
-
-
0024435166
-
New directions for macrolide antibiotics: Structural modifications and in vitro activity
-
Kirst HA, Sides GD: New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989, 33:1413-1418.
-
(1989)
Antimicrob Agents Chemother
, vol.33
, pp. 1413-1418
-
-
Kirst, H.A.1
Sides, G.D.2
-
16
-
-
0024442066
-
New directions for macrolide antibiotics: Pharmacokinetics and clinical efficacy
-
Kirst HA, Sides GD: New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989, 33:1419-1422.
-
(1989)
Antimicrob Agents Chemother
, vol.33
, pp. 1419-1422
-
-
Kirst, H.A.1
Sides, G.D.2
-
18
-
-
0029971085
-
3-keto-11,12-carbazate derivatives of 6-0-methylerythromycin A. Synthesis and in vitro activity
-
Griesgraber G, Or SY, Chu DTW, Nilius AM, Johnson PM, Flamm RK, Henry RF, Plattner JJ: 3-keto-11,12-carbazate derivatives of 6-0-methylerythromycin A. Synthesis and in vitro activity. J Antibiotics 1996, 49:465-477.
-
(1996)
J Antibiotics
, vol.49
, pp. 465-477
-
-
Griesgraber, G.1
Or, S.Y.2
Dtw, C.3
Nilius, A.M.4
Johnson, P.M.5
Flamm, R.K.6
Henry, R.F.7
Plattner, J.J.8
-
19
-
-
0343742636
-
In vitro activity of RU64004, a new ketolide antibiotic, against Grampositive bacteria
-
Schulin T, Wennersten CB, Moellering RC, Eliopoulos GM: In vitro activity of RU64004, a new ketolide antibiotic, against Grampositive bacteria. Antimicrob Agents Chemother 1997, 41:1196-1202. This is the first paper to present comprehensive data on the antibacterial activity of the development ketolide RU64004 against clinical isolates.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 1196-1202
-
-
Schulin, T.1
Wennersten, C.B.2
Moellering, R.C.3
Eliopoulos, G.M.4
-
20
-
-
0031040129
-
Oxazolidinone antibacterial agents; development of the clinical candidates eperezolid and linezolid
-
Zurenko GW, Ford CW, Hutchinson DK, Brickner SJ, Barbachyn MR: Oxazolidinone antibacterial agents; development of the clinical candidates eperezolid and linezolid. Exp Opin Invest Drugs 1997. 6:151-158. This paper discusses the mechanism of action of the oxazolidinones, their synthesis, structure-activity relationships, antibacterial spectrum and data from Phase I clinical trials.
-
(1997)
Exp Opin Invest Drugs
, vol.6
, pp. 151-158
-
-
Zurenko, G.W.1
Ford, C.W.2
Hutchinson, D.K.3
Brickner, S.J.4
Barbachyn, M.R.5
-
21
-
-
0030944770
-
Oxazolidinones: New antibacterial agents
-
Ford CW, Hamel JC, Stapert D, Moerman JK, Hutchinson DK, Barbachyn MR, Zurenko GE; Oxazolidinones: new antibacterial agents. Trends Microbiol 1997, 5:196-200. This paper describes the discovery of the oxazolidinones, their antibacterial activity and mechanism of action.
-
(1997)
Trends Microbiol
, vol.5
, pp. 196-200
-
-
Ford, C.W.1
Hamel, J.C.2
Stapert, D.3
Moerman, J.K.4
Hutchinson, D.K.5
Barbachyn, M.R.6
Zurenko, G.E.7
-
22
-
-
0030793842
-
Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
-
Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM: Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997, 41:2132-2136. This paper presents data that the mechanism of action of the oxazolidinones involves prevention of mRNA binding to the ribosome at the initiation phase of translation.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 2132-2136
-
-
Shinabarger, D.L.1
Marotti, K.R.2
Murray, R.W.3
Lin, A.H.4
Melchior, E.P.5
Swaney, S.M.6
Dunyak, D.S.7
Demyan, W.F.8
Buysse, J.M.9
-
23
-
-
0031956779
-
Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay
-
Murray RW, Schaadt RD, Zurenko GE, Marotti KR: Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay. Antimicrob Agents Chemother 1998, 42:947-950. This paper describes the isolation of an eperezolid-resistant mutant of S. aureus by prolonged drug exposure and its use to confirm that resistance (and by inference the drug target) is expressed at the level of the ribosome.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 947-950
-
-
Murray, R.W.1
Schaadt, R.D.2
Zurenko, G.E.3
Marotti, K.R.4
-
24
-
-
13344284628
-
Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity
-
Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, Glickman SE, Grega KC, Hendges SK, Toops DS et al.: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996, 39:680-685.
-
(1996)
J Med Chem
, vol.39
, pp. 680-685
-
-
Barbachyn, M.R.1
Hutchinson, D.K.2
Brickner, S.J.3
Cynamon, M.H.4
Kilburn, J.O.5
Klemens, S.P.6
Glickman, S.E.7
Grega, K.C.8
Hendges, S.K.9
Toops, D.S.10
-
25
-
-
0028194894
-
Streptogramin analogues
-
Barriere JC, Bouanchaud DH, Desnottes JF, Paris JM: Streptogramin analogues. Exp Opin Invest Drugs 1994, 3:115-131.
-
(1994)
Exp Opin Invest Drugs
, vol.3
, pp. 115-131
-
-
Barriere, J.C.1
Bouanchaud, D.H.2
Desnottes, J.F.3
Paris, J.M.4
-
26
-
-
0030660723
-
The renewed challenge of antibacterial chemotherapy
-
Niccolai D, Tarsi L, Thomas RJ: The renewed challenge of antibacterial chemotherapy. Chem Commun 1997:2333-2342. This paper reviews most of the antibacterial agents currently in development, with an emphasis on their chemical synthesis.
-
(1997)
Chem Commun
, pp. 2333-2342
-
-
Niccolai, D.1
Tarsi, L.2
Thomas, R.J.3
-
27
-
-
0030983411
-
Inhibition of protein synthesis by streptogramins and related antibiotics
-
Cocito C, Di Giambattista M, Nyssen E, Vannuffel P: Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997, 39(suppl A):7-13.
-
(1997)
J Antimicrob Chemother
, vol.39
, Issue.SUPPL. A
, pp. 7-13
-
-
Cocito, C.1
Di Giambattista, M.2
Nyssen, E.3
Vannuffel, P.4
-
28
-
-
0028106176
-
In vitro activity of the tribactam GV104326 against Gram-positive, Gram-negative, and anaerobic bacteria
-
Di Modugno E, Erbetti I, Ferrari L, Galassi G, Hammond SM, Xerri L: In vitro activity of the tribactam GV104326 against Gram-positive, Gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother 1994, 38:2362-2368.
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 2362-2368
-
-
Di Modugno, E.1
Erbetti, I.2
Ferrari, L.3
Galassi, G.4
Hammond, S.M.5
Xerri, L.6
-
29
-
-
0031983595
-
In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae
-
Sifaoui F, Varon E, Kitzis M-D, Gutmann L: In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998, 42:173-175. This paper provides evidence that the tribactam sanfetrinem promotes killing of penicillin-resistant pneumococci by interaction with penicillin-binding proteins 1a and 2b.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 173-175
-
-
Sifaoui, F.1
Varon, E.2
Kitzis, M.-D.3
Gutmann, L.4
-
30
-
-
0031908863
-
Novel C-2 substituted carbapenem derivatives. Part IV. Synthesis and biological activity of five membered heteroaromatic derivatives
-
Branch CL, Burton G, Clarke GJ, Coulton S, Douglas JD, Eglington AJ, Guest AW, Hinks JD, Hird NW, Holland RK et al.: Novel C-2 substituted carbapenem derivatives. Part IV. Synthesis and biological activity of five membered heteroaromatic derivatives. J Antibiotics 1998, 51:21 0-220. This paper describes the synthesis and properties of a range of novel carbapenems which are particularly active against community-acquired respiratory pathogens, including penicillin-resistant strains that do not produce β-lactamase.
-
(1998)
J Antibiotics
, vol.51
, pp. 210-220
-
-
Branch, C.L.1
Burton, G.2
Clarke, G.J.3
Coulton, S.4
Douglas, J.D.5
Eglington, A.J.6
Guest, A.W.7
Hinks, J.D.8
Hird, N.W.9
Holland, R.K.10
-
31
-
-
0023691243
-
Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins
-
Curtis NAC, Eisensladt RL, East SJ, Cornford RJ, Walker LA, White AJ: Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimicrob Agents Chemother 1988, 32:1879-1886.
-
(1988)
Antimicrob Agents Chemother
, vol.32
, pp. 1879-1886
-
-
Nac, C.1
Eisensladt, R.L.2
East, S.J.3
Cornford, R.J.4
Walker, L.A.5
White, A.J.6
-
32
-
-
0029893279
-
Synthesis and antibacterial activities of novel C(7)-catechol-substituted cephalosporins (I)
-
Kim Y-Z, Lim J-C, Yeo J-H, Bang C-S, Kim S-S, Lee TH, Oh SO, Moon Y-C, Lee C-S: Synthesis and antibacterial activities of novel C(7)-catechol-substituted cephalosporins (I). J Antibiotics 1996, 49:496-498.
-
(1996)
J Antibiotics
, vol.49
, pp. 496-498
-
-
Kim, Y.-Z.1
Lim, J.-C.2
Yeo, J.-H.3
Bang, C.-S.4
Kim, S.-S.5
Lee, T.H.6
Oh, S.O.7
Moon, Y.-C.8
Lee, C.-S.9
-
33
-
-
0029949956
-
Synthesis and antibacterial activities of novel C(7)-catechol-substituted cephalosporins (II)
-
Kim Y-Z, Lim J-C, Yeo J-H, Bang C-S, Kim S-S, Lee TH, Oh SH, Moon Y-C, Lee CS: Synthesis and antibacterial activities of novel C(7)-catechol-substituted cephalosporins (II). J Antibiotics 1996, 49:499-501.
-
(1996)
J Antibiotics
, vol.49
, pp. 499-501
-
-
Kim, Y.-Z.1
Lim, J.-C.2
Yeo, J.-H.3
Bang, C.-S.4
Kim, S.-S.5
Lee, T.H.6
Oh, S.H.7
Moon, Y.-C.8
Lee, C.S.9
-
34
-
-
0030902573
-
Antibacterial activity of BMS-180680, a new catechol-containing monobactam
-
Fung-Tomc J, Bush K, Minassian B, Kolek B, Flamm R, Gradelski E, Bonner D: Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother 1997, 41:1010-1016. This paper presents evidence that the investigational compound BMS-180680 utilises TonB-dependent transport systems for enhanced uptake across the bacterial outer membrane, which results in potent in vitro activity against several organisms, including Pseudomonas aeruginosa.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 1010-1016
-
-
Fung-Tomc, J.1
Bush, K.2
Minassian, B.3
Kolek, B.4
Flamm, R.5
Gradelski, E.6
Bonner, D.7
-
35
-
-
0030751187
-
Beyond vancomycin: New therapies to meet the challenge of glycopeptide resistance
-
Nicas TI, Zeckel ML, Braun DK: Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Trends Microbiol 1997, 5:240-249. This paper considers the current problems of resistance in Gram-positive pathogens and discusses the discovery and development of new glycopeptides, streptogramins and oxazolidinones.
-
(1997)
Trends Microbiol
, vol.5
, pp. 240-249
-
-
Nicas, T.I.1
Zeckel, M.L.2
Braun, D.K.3
-
36
-
-
0027266017
-
Genetics and mechanisms of glycopeptide resistance in enterococci
-
Arthur M, Courvalin P: Genetics and mechanisms of glycopeptide resistance in enterococci, Antimicrob Agents Chemother 1993, 37:1563-1571.
-
(1993)
Antimicrob Agents Chemother
, vol.37
, pp. 1563-1571
-
-
Arthur, M.1
Courvalin, P.2
-
37
-
-
0031038392
-
Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues
-
Allen NE, Le Tourney DL, Hobbs JN: Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Antimicrob Agents Chemother 1997, 41:66-71 This paper presents data on the binding affinities of LY191145 and vancomycin for residues in peptidoglycan, and the dimerisation constants of these glycopeptides.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 66-71
-
-
Allen, N.E.1
Le Tourney, D.L.2
Hobbs, J.N.3
-
38
-
-
0030841073
-
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
-
Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40:135-136.
-
(1997)
J Antimicrob Chemother
, vol.40
, pp. 135-136
-
-
Hiramatsu, K.1
Hanaki, H.2
Ino, T.3
Yabuta, K.4
Oguri, T.5
Tenover, F.C.6
-
39
-
-
0003963058
-
-
London: John Wiley and Sons
-
Gale EF, Cundliffe E, Reynolds PE, Richmond MH, Waring MJ: The Molecular Basis of Antibiotic Action, edn 2. London: John Wiley and Sons; 1981.
-
(1981)
The Molecular Basis of Antibiotic Action, Edn 2
-
-
Gale, E.F.1
Cundliffe, E.2
Reynolds, P.E.3
Richmond, M.H.4
Waring, M.J.5
-
40
-
-
0031975655
-
The therapeutic potential of cationic peptides
-
Hancock REW: The therapeutic potential of cationic peptides. Exp Opin Invest Drugs 1998, 7:167-174. This review describes the properties of various cationic peptides with an emphasis on their development as therapeutic agents.
-
(1998)
Exp Opin Invest Drugs
, vol.7
, pp. 167-174
-
-
Rew, H.1
-
41
-
-
0032007854
-
Cationic peptides: A new source of antibiotics
-
Hancock REW, Lehrer R: Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998, 16:82-88. This review describes the properties and potential applications of cationic peptides and provides more detailed descriptions of their structures and mode of action than [40"].
-
(1998)
Trends Biotechnol
, vol.16
, pp. 82-88
-
-
Rew, H.1
Lehrer, R.2
-
42
-
-
23444440823
-
Inactivation of antibiotics and the dissemination of resistance genes
-
Davies J: Inactivation of antibiotics and the dissemination of resistance genes. Science 1994, 264:375-382.
-
(1994)
Science
, vol.264
, pp. 375-382
-
-
Davies, J.1
-
43
-
-
0031007336
-
Conditionally lethal Escherichia coli mutants contain point defects that map to regions conserved among murein and folyl poly-γ-glutamate ligases: Identification of a ligase superfamily
-
Eveland SS, Pompliano DL, Anderson MS: Conditionally lethal Escherichia coli mutants contain point defects that map to regions conserved among murein and folyl poly-γ-glutamate ligases: identification of a ligase superfamily. Biochemistry 1997, 36:6223-6229.
-
(1997)
Biochemistry
, vol.36
, pp. 6223-6229
-
-
Eveland, S.S.1
Pompliano, D.L.2
Anderson, M.S.3
-
44
-
-
0030763951
-
Novel targets for antibiotics - An update
-
Isaacson RE: Novel targets for antibiotics - an update. Exp Opin Invest Drugs 1997, 6:1009-1017. This paper considers the opportunities for inhibiting bacterial Infection processes with drugs and the benefits this approach would have for minimising selection of drug-resistant variants.
-
(1997)
Exp Opin Invest Drugs
, vol.6
, pp. 1009-1017
-
-
Isaacson, R.E.1
-
45
-
-
0030970590
-
Inhibition of virulence factors in bacteria
-
Goldschmidt RM, Macielag MJ, Hlasta DJ, Barrett JF: Inhibition of virulence factors in bacteria. Curr Pharm Des 1997, 3:125-142. This paper provides a comprehensive review of new opportunities for inhibition of bacterial infection processes and describes some investigational compounds that appear to either affect infection processes directly, or prevent the organisms from adapting to an in vivo environment.
-
(1997)
Curr Pharm des
, vol.3
, pp. 125-142
-
-
Goldschmidt, R.M.1
Macielag, M.J.2
Hlasta, D.J.3
Barrett, J.F.4
|